United States Drug Patent 8,227,490: Claim Scope, Expiration, Litigation Risk and Ciclopirox Patent Landscape

US 8,227,490 protects a narrowly defined method of treating human seborrheic dermatitis with a single ciclopirox-containing composition. The claim requires five substantive conditions: treatment of seborrheic dermatitis, administration to affected human skin, ciclopirox as the only active ingredient, at least one surfactant, and a composition pH of approximately 4.5 to 6.5. The claim also requires administration of a single composition.

The patent does not broadly cover every ciclopirox product or every seborrheic dermatitis treatment. Its commercial relevance depends on whether a marketed or proposed product has ciclopirox as its sole active ingredient, uses a surfactant-containing formulation, falls within the claimed pH range, and is labeled or used for seborrheic dermatitis.

What does US Patent 8,227,490 claim?

The supplied independent claim is a method-of-treatment claim directed to seborrheic dermatitis. Its operative limitations are:

Claim limitation	Scope
Patient	A human
Disease	Seborrheic dermatitis
Administration site	Affected area of the skin
Therapeutic agent	Ciclopirox
Active-ingredient limitation	Ciclopirox must be the only active ingredient
Formulation requirement	At least one surfactant
pH	About 4.5 to about 6.5
Dosage form or treatment structure	A single composition
Quantity	An amount effective to treat seborrheic dermatitis

The claim is written as a method claim rather than a composition claim. Direct infringement therefore generally requires performance of the treatment method, while a manufacturer’s exposure may arise through inducing or contributing to infringement under 35 U.S.C. § 271(b) and (c), depending on labeling, instructions, formulation, and evidence of intended use.

How does the "only one active ingredient" limitation affect scope?

The phrase "comprising only one active ingredient, the active ingredient consisting of ciclopirox" is a major narrowing limitation.

A formulation containing ciclopirox plus a second pharmacologically active ingredient would fall outside the literal scope of the claim. Examples potentially outside the claim include a composition containing ciclopirox and:

Ketoconazole
Zinc pyrithione
Selenium sulfide
Salicylic acid
Coal tar
A topical corticosteroid
An antibacterial or antifungal active other than ciclopirox

The claim remains compatible with numerous inactive excipients. The presence of water, preservatives, viscosity modifiers, fragrances, buffers, emollients, solvents, conditioning agents, and surfactants does not by itself defeat the "only one active ingredient" limitation.

The principal technical issue is whether a salt or complex of ciclopirox qualifies as ciclopirox for claim purposes. Ciclopirox olamine may raise claim-construction questions depending on the patent specification, prosecution history, and whether the claim uses "ciclopirox" as the active moiety or as a specific chemical form. A generic manufacturer would normally assess this issue together with the product’s labeling and pharmaceutical equivalence position.

What does "at least one surfactant" cover?

"At least one surfactant" is broad in chemical identity but still requires the ingredient to function as a surfactant. The limitation can potentially cover anionic, nonionic, amphoteric, and cationic surfactants, subject to the patent specification and ordinary technical meaning.

Potentially relevant surfactants include:

Sodium laureth sulfate
Sodium lauryl sulfate
Cocamidopropyl betaine
Alkyl polyglucosides
Polysorbates
Amphoteric betaines
Other cleansing or solubilizing surfactants

A product containing ciclopirox in a vehicle without a qualifying surfactant may avoid literal infringement. A formulation containing a multifunctional excipient can create a dispute over whether that ingredient is a surfactant, a solubilizer, an emulsifier, or another excipient under the claim construction.

How important is the pH range of 4.5 to 6.5?

The pH limitation is central. A product with a measured pH materially below 4.5 or above 6.5 would not literally satisfy this element. The word "about" creates an evidentiary margin, but it does not eliminate the numerical limitation.

A product comparison should account for:

The formulation’s specification range
Release testing limits
Actual batch results
The pH measurement method
Temperature and dilution conditions
Whether pH changes during storage
Whether the patent specification defines "about"

A proposed product specified at pH 5.0 presents substantially greater literal-overlap risk than a product consistently specified at pH 7.0. A formulation near the boundary may create both literal-infringement and doctrine-of-equivalents issues.

What formulations are protected by US 8,227,490?

The supplied claim potentially covers a shampoo, cleanser, wash, gel, foam, lotion, cream, emulsion, or other topical composition if the formulation satisfies the claim limitations.

The claim does not expressly require:

A shampoo dosage form
A particular ciclopirox concentration
Ciclopirox olamine
A specific surfactant
A particular administration frequency
A specific treatment duration
A particular container
A prescription-only product
A particular manufacturing process

This breadth is offset by the claim’s pH, single-active, surfactant, and seborrheic-dermatitis limitations.

Formulation overlap matrix

Product characteristic	Literal-overlap risk
Ciclopirox as sole active, surfactant present, pH 4.5-6.5	High
Ciclopirox as sole active, no surfactant	Low for claim 1
Ciclopirox plus ketoconazole	Low for claim 1
Ciclopirox shampoo at pH 7.0	Lower, subject to "about" construction
Ciclopirox cream without surfactant	Low for claim 1
Ciclopirox formulation used for psoriasis only	Lower, unless seborrheic dermatitis is an intended or actual use
Ciclopirox product with a separate second treatment product	Potentially outside the single-composition limitation
Ciclopirox product with multiple active ingredients in one composition	Low for claim 1

"Comprising" generally keeps the formulation open to additional non-active ingredients. It does not, however, neutralize the express requirement that ciclopirox be the only active ingredient.

When does US 8,227,490 lose exclusivity?

US 8,227,490 B2 issued on July 24, 2012. The enforceable term is determined by the patent family’s earliest effective nonprovisional filing date, applicable patent-term-adjustment calculation, and any terminal disclaimer. Under 35 U.S.C. § 154, a post-June 8, 1995 utility patent generally receives a term of 20 years from the earliest effective nonprovisional filing date, subject to adjustments and disclaimers.

The issue date alone does not establish the expiration date. The controlling record is the USPTO Patent Center continuity and patent-term data for US 8,227,490, together with any terminal-disclaimer information. The patent’s enforceability also depends on maintenance-fee payment status and any post-grant judicial order.

What exclusivity applies to ciclopirox products?

Patent exclusivity and FDA regulatory exclusivity are separate.

Exclusivity category	Relevance
Patent term	Controls enforceable patent rights, subject to validity and infringement
New chemical entity exclusivity	Generally not a current barrier for an old ciclopirox product
Three-year clinical-investigation exclusivity	Could apply to a qualifying supplemental approval, but does not automatically block all generic development
Orphan-drug exclusivity	Not generally associated with ordinary seborrheic dermatitis products
Pediatric exclusivity	Requires a specific FDA grant
Orange Book listing	Matters for ANDA notice and Paragraph IV procedures

Ciclopirox has been marketed for decades, so a generic applicant’s principal barrier is generally patent and regulatory strategy rather than new chemical entity exclusivity.

What is the Orange Book status of US 8,227,490?

The Orange Book question must be analyzed at the reference-listed-drug and product level. A patent may be relevant to an approved drug without being listed in the Orange Book. Method-of-use patents can be listed when they claim an approved use and satisfy FDA listing requirements, but listing is not automatic merely because a patent covers a method associated with a drug.

For ciclopirox shampoo products, the relevant regulatory records include:

The FDA Orange Book patent and exclusivity listings
The reference-listed-drug record
The approved prescribing information
The product’s NDA history
Any patent-listing dispute or delisting record
Approved indications and dosing instructions

The Orange Book listing status of US 8,227,490 should be verified against the current FDA Orange Book and the specific ciclopirox product. The patent’s existence alone does not establish that it remains listed, that it is enforceable, or that it creates an ANDA stay.

How would a generic applicant challenge this patent?

A generic applicant could use several strategies.

Paragraph IV certification

If US 8,227,490 is listed for the relevant reference product, an ANDA applicant could submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed. The certification can trigger patent litigation under the Hatch-Waxman framework.

The main noninfringement arguments would likely focus on:

A product pH outside the claimed range
Absence of a surfactant
Presence of a second active ingredient
A label that omits seborrheic dermatitis
A product not administered as a single composition
A dosage form or formulation that does not satisfy the claim

The main invalidity arguments could focus on:

Anticipation by earlier ciclopirox formulations or treatment methods
Obviousness based on prior ciclopirox topical products, surfactants, and known pH ranges
Written-description or enablement issues
Indefiniteness concerning "about," "effective," "surfactant," or "only one active ingredient"
Claim-construction disputes over ciclopirox salts

Section viii statement

If the patent claims only a method of use and the relevant use is not required by the generic label, an ANDA applicant may consider a Section viii statement. This strategy depends on the patent’s listing, the approved labeling, the scope of the patented indication, and whether the generic label can omit the protected use while remaining approvable.

A Section viii strategy is more difficult when the reference product’s principal approved indication is the patented use or when the labeling necessarily instructs the patented method.

Formulation redesign

A generic manufacturer could attempt to design around claim 1 by:

Adjusting pH outside the claimed range
Using a formulation without a surfactant
Adding a second active ingredient
Pursuing a different dosage form
Omitting seborrheic dermatitis from the label where legally and regulatorily permissible
Separating treatment steps into distinct compositions

Each design-around may create new regulatory, stability, tolerability, or patent risks. Avoiding claim 1 does not avoid other patents in the family or unrelated composition, manufacturing, or method-of-use claims.

Which companies are challenging ciclopirox patent rights?

The relevant competitive group includes:

The NDA holder and its successor or licensee.
Generic manufacturers seeking approval for ciclopirox shampoo, cream, gel, or topical solution.
Contract manufacturers supplying generic or private-label products.
Companies developing combination antifungal or seborrheic dermatitis therapies.

A public company name should not be treated as a confirmed Paragraph IV challenger unless supported by an ANDA litigation complaint, FDA notice record, or federal court docket. ANDA applicants often remain undisclosed until litigation begins.

The principal branded product historically associated with ciclopirox shampoo is Loprox, while generic ciclopirox products have been approved in multiple topical dosage forms. Product-level competition is shaped by dosage form, concentration, prescription status, indication, and payer substitution rather than by the US 8,227,490 claim alone.

What is the broader ciclopirox patent landscape?

The landscape has four principal layers.

Earlier ciclopirox composition and antifungal patents

Older patents cover ciclopirox, ciclopirox olamine, topical vehicles, antifungal compositions, and broad dermatological uses. Many early compound and formulation rights are likely expired or commercially weak because of age. They remain relevant as prior art against later patents and as evidence for obviousness analyses.

Shampoo and surfactant formulations

A separate group covers ciclopirox shampoos, cleansers, surfactant systems, solubilization, viscosity control, and product stability. These patents may overlap technically with claim 1 but differ in concentration, excipient identity, pH, dosage form, or manufacturing process.

Method-of-use patents

Method patents may target:

Seborrheic dermatitis
Dandruff
Tinea and dermatophyte infections
Malassezia-associated disorders
Scalp treatment
Treatment frequency and contact time

US 8,227,490 is commercially relevant because it ties ciclopirox treatment to seborrheic dermatitis and a defined formulation profile.

Manufacturing and delivery patents

Manufacturing rights may concern:

Preparation of ciclopirox or ciclopirox olamine
Particle-size control
Homogenization
Preservation
Packaging
Foam or shampoo delivery
Stability during storage

These rights can create freedom-to-operate issues even when the principal treatment claim is avoided.

How strong is the patent estate for US 8,227,490?

The strength of claim 1 is mixed.

Strengths

The claim combines treatment, active ingredient, surfactant, pH, and single-composition limitations.
The pH range can be objectively tested.
The sole-active limitation may distinguish combination products.
A commercial ciclopirox shampoo labeled for seborrheic dermatitis could satisfy the intended-use element.
Formulation records, batch specifications, and labeling can provide direct evidence.

Weaknesses

The claim is narrow because every limitation must be met.
pH can often be altered through routine formulation work.
A second active ingredient may avoid the sole-active limitation.
A non-surfactant dosage form may avoid the claim.
"About" and "effective" can create claim-construction disputes.
Prior-art ciclopirox topical and shampoo products may support anticipation or obviousness challenges.
A method-of-use claim may be vulnerable to label modification or Section viii strategies.

The patent is strongest against a single-active ciclopirox shampoo or cleanser formulated within the claimed pH range and labeled specifically for seborrheic dermatitis. It is weaker against combination products, non-surfactant formulations, and products with pH clearly outside the claimed range.

What patent litigation affects ciclopirox generic entry?

A litigation assessment should examine:

Issue	Commercial consequence
Orange Book listing	Determines whether a Paragraph IV notice can trigger a statutory stay
Patent expiration	Determines the latest ordinary patent barrier
ANDA filing date	Controls first-filer and litigation timing
30-month stay	Can delay FDA approval if statutory conditions are met
Preliminary injunction	May affect launch beyond ordinary Hatch-Waxman timing
Settlement agreement	May establish an agreed generic entry date
Authorized generic	Can reduce expected first-filer economics
Patent delisting	May eliminate Orange Book-based litigation leverage
Label carve-out	May permit approval without the patented indication

No settlement or court judgment should be inferred from the patent’s issuance. A confirmed litigation position requires a complaint, docket entry, final judgment, consent judgment, or settlement-related public filing.

What revenue exposure is associated with the patent?

Revenue exposure cannot be assigned to US 8,227,490 from the claim text alone. The commercial analysis depends on:

Annual sales of the specific reference product
Whether the patent is listed
Whether the product’s principal indication falls within claim 1
Number of approved generic competitors
Generic pricing and substitution
Availability of ciclopirox products in other dosage forms
Whether the branded product remains actively marketed
The remaining enforceable patent term
Whether an authorized generic is launched

A method claim covering one ciclopirox formulation does not necessarily protect the entire ciclopirox franchise. Revenue can migrate to creams, gels, solutions, combination products, or non-prescription dandruff products outside the claim.

What geographic coverage does US 8,227,490 provide?

US 8,227,490 provides rights only in the United States. It does not directly block:

Manufacture and sale entirely outside the United States
Foreign marketing
Foreign regulatory approval
Products covered only by foreign counterparts

However, US patent law can reach certain importation, supply, inducement, and component activities under 35 U.S.C. § 271. The international patent position must be assessed separately through the patent family, national-phase filings, prosecution outcomes, and expiration dates in each jurisdiction.

Key Takeaways

US 8,227,490 claim 1 is a narrow method claim for treating human seborrheic dermatitis.
The formulation must contain ciclopirox as the only active ingredient and at least one surfactant.
The claimed pH is about 4.5 to about 6.5.
The claim requires administration of a single composition to affected skin.
A ciclopirox product with a second active ingredient, no surfactant, or a clearly different pH may avoid literal infringement.
The claim can cover multiple topical dosage forms because it does not expressly require a shampoo.
Patent-term analysis requires the USPTO continuity, patent-term-adjustment, terminal-disclaimer, and maintenance-fee records.
Orange Book relevance must be determined for the specific reference-listed drug and current listing status.
Paragraph IV, Section viii, formulation redesign, and invalidity challenges are the main generic-entry strategies.
The patent is strongest against a single-active ciclopirox shampoo or cleanser within the claimed pH range and labeled for seborrheic dermatitis.
Older ciclopirox compound and formulation patents remain important as prior art even where their patent terms have expired.

FAQs

Can a ciclopirox shampoo with ketoconazole infringe claim 1?

It would generally have a strong noninfringement position against the express "only one active ingredient" limitation, subject to the patent’s full claim set and any separate patents covering combination products.

Does a ciclopirox cream fall within US 8,227,490?

Potentially, because claim 1 does not expressly require a shampoo. The cream would still need a surfactant, a pH of about 4.5 to 6.5, ciclopirox as the only active ingredient, a seborrheic dermatitis use, and administration as a single composition.

Can changing formulation pH avoid the patent?

A pH clearly outside approximately 4.5 to 6.5 may avoid literal infringement of claim 1. The result depends on the construction of "about," testing methodology, and possible doctrine-of-equivalents arguments.

Does the patent cover ciclopirox manufacturing?

The supplied claim does not cover manufacturing. It is directed to treatment of seborrheic dermatitis. Separate process or composition claims in the patent or related family would need independent analysis.

Are biosimilar rules relevant to ciclopirox?

No. Ciclopirox is a small-molecule drug, so generic-drug rules under the Hatch-Waxman Act, including ANDA and Paragraph IV procedures, are generally relevant rather than biosimilar procedures under the Biologics Price Competition and Innovation Act.

References

United States Patent and Trademark Office. (2012). United States Patent No. 8,227,490 B2.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
U.S. Code, Title 35, §§ 154, 271, and 282.
U.S. Code, Title 21, § 355.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, §§ 2111, 2111.03, and 2173.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	196 39 818	Sep 27, 1996

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	008860	⤷ Start Trial
Austria	209891	⤷ Start Trial
Australia	4774697	⤷ Start Trial
Australia	716208	⤷ Start Trial
Bulgaria	103260	⤷ Start Trial
Bulgaria	64365	⤷ Start Trial
Brazil	9711575	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,227,490

Summary for Patent: 8,227,490